Genitourinary Cancers

>

Latest News

Positive Efficacy Noted With Cemiplimab/Chemotherapy in Penile Carcinoma
Positive Efficacy Noted With Cemiplimab/Chemotherapy in Penile Carcinoma

February 15th 2025

The phase 2 EPIC trial assessing patients with penile carcinoma met its primary end point of clinical benefit rate, with the lower bound of the confidence interval exceeding the null hypothesis limit.

Promising Clinical Activity in UTUC Lesions With Enfortumab Vedotin Plus Pembrolizumab
Promising Clinical Activity in UTUC Lesions With Enfortumab Vedotin Plus Pembrolizumab

February 14th 2025

The 2025 Genitourinary Cancers Symposium will feature key updates in the management of different bladder, prostate, and kidney cancer populations.
A Look at Upcoming Impactful Presentations at ASCO GU 2025

February 12th 2025

The decision follows phase 3 EV-302 trial findings showing improved survival with enfortumab vedotin plus pembrolizumab vs chemotherapy in urothelial cancer.
Enfortumab Vedotin Combo Gains European Approval for Urothelial Cancer

August 29th 2024

Additionally, the 48-month overall survival rate was higher with nivolumab/cabozantinib vs sunitinib in the phase 3 CheckMate 9ER trial.
Frontline Nivolumab Combo Improves TFS Vs Sunitinib in Advanced RCC

June 9th 2024

Latest CME Events & Activities

2025 GU Satellite Symposia in San Francisco

February 13-14, 2025

Register Now!

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Register Now!

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

<1
...
4849505152